Drug Index


Mechanism :

Omeprazole belongs to a class of antisecretory compounds, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.

Indication :

  • Gastro-esophageal reflux
  • Esophageal gastric varices bleeding prophylaxis, erosive esophagitis
  • Acid peptic disease resistant to ranitidine
  • Helicobacter pylori eradication
  • Fat malabsorption despite optimal use of replacement in cystic fibrosis

Contraindications :

Contraindicated in patients with known hypersensitivity to any component of the formulation. Treatment with omeprazole may mask the symptoms of other gastric disease. Caution should be exercised in patients with hepatic impairment.

Dosing :

GERD: >1 year; Esophageal erosion:1 month-1 year.
Give orally before meals. May treat upto 6 weeks-2 months.
Start with 1 mg/kg/day in one-two divided doses. Can increase dose to 2 to 3.5 mg/kg/day.
Neonatal duodenal ulcer/reflux esophagitis:
0.5-1.5 mg/kg orally, every day for upto 2 months.

Adverse Effect :

Headache, dizziness, rash, urticaria, pruritus, diarrhea, gastric glandular cysts (on prolonged treatment), cough, upper respiratory infection, irreversible visual impairment in critically ill patients who have received high doses of IV omeprazole. Others: blood dyscrasias, hepatic impairment, hypersensitivity reaction, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancreatitis, interstitial nephritis, rhabdomyolysis, fractures, hyponatremia, hypomagnesemia (long-term use), atrophic gastritis (long-term use), clostridium difficile associated diarrhea, headache, nausea/vomiting, diarrhea, thrombophlebitis (IV use), abdominal pain, fever, rash, dizziness,

flatulence, arthralgia.

Interaction :

Diazepam, Warfarin and Phenytoin: Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly.
Ampicillin Esters, Iron Salts: omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability.
Tacrolimus: Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.
Atazanavir: Concomitant administration of omeprazole has been reported to reduce the plasma levels of atazanavir.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Dosing is recommended as 50%, for maintenance for healing of erosive esophagitis.
01/19/2024 01:49:55 Omeprazole
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0